Odyssey Therapeutics Raises $279 Million in Upsized IPO to Fund Mid-Stage Autoimmune Program
Odyssey Therapeutics sold 15.5 million shares at $18 each in an upsized U.S. initial public offering, generating $279 million in proceeds. The Boston company will use the funds mainly to advance clinical work on OD-001, a therapy now in a mid-stage trial for ulcerative colitis, and for general corporate purposes. The IPO comes amid a broader resurg…